Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.

@article{MorenoAspitia2009AnthracyclineAT,
  title={Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.},
  author={Alvaro Moreno-Aspitia and Edith A. Perez},
  journal={Clinical therapeutics},
  year={2009},
  volume={31 8},
  pages={1619-40}
}
BACKGROUND As many as 30% of women diagnosed with early breast cancer (BC) will eventually progress to or relapse with locally advanced or meta-static BC. Resistance to the commonly used chemotherapies anthracyclines and taxanes, as well as the approval of new pharmacologic options for treating BC, present important clinical, cost-effectiveness, and societal challenges. OBJECTIVES The aims of this work were as follows: (1) to review published evidence for potential management strategies… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 89 references

Capecitabine is associated with lower chemotherapy - related expenditures than those associated with gemcitabine in women with metastatic breast cancer

  • M Lee, KL Schulman, S Zelt
  • Cancer Res
  • 2009

Ixabepi - lone plus capecitabine improves progression - free survival in patients with metastatic breast cancer resistant to taxanes : A pooled analysis from two phase III studies

  • J Ro
  • Cancer Res
  • 2009

Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies

  • P Conte, H Roché, EA Perez
  • Cancer Res
  • 2009

Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepi - lone in the first line setting : A pooled analysis from two phase II studies

  • L Vahdat, LE Fein, MW Karwai
  • Cancer Res
  • 2009

Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors : A pooled analysis of patients from two large phase III clinical studies

  • HS Rugo, H Roché, E Thomas
  • Cancer Res
  • 2009

Similar Papers

Loading similar papers…